- Home
- CGEN vs OXSQ Comparison
CGEN vs OXSQ Comparison
Compare CGEN & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- OXSQ
- Stock Information
- Founded
- CGEN 1993
- OXSQ 2003
- Country
- CGEN Israel
- OXSQ United States
- Employees
- CGEN N/A
- OXSQ N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- OXSQ Blank Checks
- Sector
- CGEN Health Care
- OXSQ Finance
- Exchange
- CGEN Nasdaq
- OXSQ Nasdaq
- Market Cap
- CGEN 125.3M
- OXSQ 144.4M
- IPO Year
- CGEN 2000
- OXSQ N/A
- Fundamental
- Price
- CGEN $1.58
- OXSQ $1.92
- Analyst Decision
- CGEN
- OXSQ
- Analyst Count
- CGEN 0
- OXSQ 0
- Target Price
- CGEN N/A
- OXSQ N/A
- AVG Volume (30 Days)
- CGEN 522.7K
- OXSQ 757.9K
- Earning Date
- CGEN 11-10-2025
- OXSQ 11-04-2025
- Dividend Yield
- CGEN N/A
- OXSQ 21.99%
- EPS Growth
- CGEN N/A
- OXSQ N/A
- EPS
- CGEN N/A
- OXSQ N/A
- Revenue
- CGEN $22,144,000.00
- OXSQ $40,142,565.00
- Revenue This Year
- CGEN N/A
- OXSQ N/A
- Revenue Next Year
- CGEN $208.08
- OXSQ $0.12
- P/E Ratio
- CGEN N/A
- OXSQ N/A
- Revenue Growth
- CGEN N/A
- OXSQ N/A
- 52 Week Low
- CGEN $1.13
- OXSQ $1.56
- 52 Week High
- CGEN $2.66
- OXSQ $2.96
- Technical
- Relative Strength Index (RSI)
- CGEN 44.43
- OXSQ 56.13
- Support Level
- CGEN $1.61
- OXSQ $1.83
- Resistance Level
- CGEN $1.80
- OXSQ $1.95
- Average True Range (ATR)
- CGEN 0.11
- OXSQ 0.06
- MACD
- CGEN -0.03
- OXSQ 0.02
- Stochastic Oscillator
- CGEN 19.35
- OXSQ 85.42
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.